- Accesswire•20 hours agoBiotech's Rise Shows No Sign of Slowing Down in 2017: Today's Reports on IntelliPharmaCeutics and Orexigen Therapeutics
NEW YORK, NY / ACCESSWIRE / February 27, 2017 / The Biotech Industry has posted some impressive gains since Election Day and the rally has continued for the larger part of this year. Both the iShares NASDAQ ...
- PR Newswire•21 days ago
SAN DIEGO, Feb. 7, 2017 /PRNewswire/ -- Orexigen Therapeutics, Inc. (NASDAQ: OREX) today announced that management will be presenting at two upcoming investor conferences. The details are as follows: ...
- PR Newswire•last monthOrexigen Therapeutics Announces Spanish Launch of Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Partnership with Laboratorios Farmacéuticos Rovi, S.A.
SAN DIEGO, Jan. 25, 2017 /PRNewswire/ -- Orexigen Therapeutics, Inc. (OREX) today announced that Laboratorios Farmacéuticos Rovi, S.A. (ROVI) has launched Mysimba in Spain. Mysimba is approved by the European Medicines Agency for the management of weight in adult patients (≥18 years) with an initial Body Mass Index (BMI) of ≥ 30 kg/m2 (obese), or ≥ 27 kg/m2 to
OREX : Summary for Orexigen Therapeutics, Inc. - Yahoo Finance
Orexigen Therapeutics, Inc. (OREX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||4.22 x 400|
|Ask||5.30 x 1000|
|Day's Range||4.33 - 4.66|
|52 Week Range||1.65 - 8.50|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-3.83|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|